Miguel Chillón

Miguel Chillón

Universitat Autònoma de Barcelona

Life & Medical Sciences

Born in Barcelona in 1966. PhD in Genetics at Hospital Duran i Reynals and Universitat de Barcelona, 1994. National Award in Human Genetics by the Spanish Association of Human Genetics in 1995. HHMI postdoctoral fellow on Gene Therapy for Cystic Fibrosis, at the Internal Medicine Dept, University of Iowa, USA (1994-1997). EMBO fellow in Genethon III (Evry, France) (1997-1999) on Development of viral vectors for Gene Therapy. Postdoctoral fellow on Gene Therapy (2000-2001) at the Universitat Autònoma de Barcelona (UAB). ICREA Research Professor at the UAB since 2001. Director of the Vector Production Unit, a technological platform to produce viral vectors, since 2004. Assistant Professor of the Biochemistry and Molecular Biology Dept. at the UAB since 2005. Co-founder of two spin-off companies in biotechnology, NanoTherapix in 2009, and Kogenix Therapeutics in 2016. He has published more than 80 papers and generated 8 patents in viral vectors.

Research interests

Medicine still has many challenges to solve especially on complex diseases where a large number of both, genetic and environmental factors, are involved. Among them, aging-associated diseases and rare disorders have attracted attention because there are no effective curative treatments for them. Some of these diseases affect the central nervous system, which in addition, is difficult to access and to manipulate with classical pharmacological treatments. To address these problems we have focused our research interests on three main objectives: (1) gene therapy strategies for diseases affecting the nervous system, such as rare neuromuscular and neurodegenerative disorders; (2) gene therapy strategies using chronokines for cognitive decline and dementia; and (3) development of more efficient and less immunogenic viral vectors.

Selected publications

– Sanchez A, Garcia-Lareu B, Puig M, Prat E, Ruberte J, Chillon M, Nunes V, Estevez R & Bosch A 2020, ‘Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy‘, Neurotherapeutics, 17, 2041–2053.

– Bosch A & Chillon M 2020, ‘Gene Therapy Approaches in CNS Regenerative Medicine‘, in Handbook of Innovations in Central Nervous System Regenerative Medicine. USA. Elsevier. Pages 375-398.

Selected research activities

Currently, Chair of the Advance Therapies Platform of EATRIS (European Infrastructure for Translational Medicine), and member of the Governing Board of the Institute of Neurosciences at UAB.